Phytopharm: Chinese cash burn
Article Abstract:
Phytopharm produces herbal medicines and tests plant materials on human subjects rather than isolating active ingredients. The quality and consistency of drug batches may not be easy to achieve, and regulatory approval is not certain. This means that investors in the company's share issue may be running risks. Fisons is a development partner, but Phytopharm still gives cause for concern over cash flow needs and could be too dependent on a single partner.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Stop taking the tablets
Article Abstract:
Powderjet Pharmaceuticals plans a 110 million pounds sterling stock flotation in May 1997. The company has developed a drug delivery system which is efficient compared to oral methods, and which is preferred by patients to injections. The system has clear benefits but there are still doubts because it is not suitable for some 90% of pharmaceuticals and has not yet gone into phase 2 trials. The stock issue represents some risk for investors.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
GeneMedix
Article Abstract:
UK generic drugs producer GeneMedix's strategy leaves the firm vulnerable to competition and tighter patent rules, and its shares could decline further. GeneMedix makes unbranded copies of drugs, selling them to countries where the drugs are not covered by patents.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The rise of wealth management. Covering all the bases. Avoiding the annuity trap
- Abstracts: Dynamics of investing. A stake that's up in the air. Shrewd operators
- Abstracts: How to discriminate. Go for the substance. Strength through harmony
- Abstracts: The same old changes again. Good timing. Shed those shackles
- Abstracts: Open software: can you afford it? Can you avoid it? Preparing for the real knowledge organization. Rapid skill obsolescence in an IT company: a case study of Acxiom Corp